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Abstract OBJECTIVE: Vitamin D deficiency has been linked to a higher risk of cancer. There 
is insufficient data regarding the influence of treatment on vitamin D status. The 
aim of this study was to compare pre- and post-treatment levels of 25(OH)D in 
premenopausal and postmenopausal women with breast cancer with a different 
receptor status (ER-estrogen receptors, PR-progesterone receptors) and in healthy 
controls. 
METHODS: 49 patients with breast cancer (23 premenopausal), and 28 healthy 
controls matched for age, menopausal status and BMI. 
RESULTS: The pre-treatment levels of 25(OH)D in patients with breast cancer 
were significantly lower in comparison to the control group (19 ng/mL vs. 
30 ng/mL, p<0.001), the lowest in premenopausal women (18.4 ng/mL). After the 
treatment period, a significant decrease in 25(OH)D level (mean 15.8 ng/mL) was 
observed. The pre-treatment level of 25(OH)D was significantly lower in patients 
with ER (16.1 vs. 23.9 ng/mL, p=0.02) and with PR (15 vs. 24.4 ng/mL, p=0.003). 
The mean pre- and post-treatment levels of 25(OH)D were lower in patients with 
Ki67 <21% (16.7 vs. 20.1 ng/mL, p=0.15; 12.5 vs. 18.1 ng/mL, p=0.02 respectively).
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CONCLUSIONS: 25(OH)D level is lower in patients 
with breast cancer in comparison to healthy women, 
regardless of their menopausal status. The lowest levels 
are found in patients with ER and PR positive tumours. 
While a significant decrease in 25(OH)D level during 
the course of therapy is observed, the supplementation 
of vitamin D should be considered. 
INTRODUCTION
Vitamin D is a group of steroid-like molecules which 
are similar to classical steroid hormones. The main bio-
logical role of vitamin D is the maintenance of calcium 
homeostasis by increasing intestinal absorption of cal-
cium and decreasing its excretion by the kidneys (Leys-
sens et al. 2013; Feldman et al. 2014; Christakos et al. 
2016). Nevertheless, vitamin D has also been implicated 
in several other biological processes such as the induc-
tion of apoptosis, modulating the immune system, 
inhibiting inflammation, blocking cell proliferation 
and promoting cell differentiation (Leyssens et al. 2013; 
Feldman et al. 2014; Christakos et al. 2016). Because of 
its pleiotropic actions, vitamin D has been widely inves-
tigated in several different diseases, especially in cancer 
(Feldman et al. 2014). Previously published studies sug-
gest that higher levels of 25-hydroxyvitamin D [25(OH)
D] are variably associated with lower breast cancer 
risk, especially in postmenopausal women (Bauer et al. 
2013; Wang et al. 2013). The data regarding the role of 
25(OH)D and breast cancer risk in younger age groups 
is conflicting (Abbas et al.,2008). Also the association 
between circulating vitamin D levels and breast cancer 
risk with regard to different subtypes based on clinical 
markers such as estrogen receptors (ER) and progester-
one receptors (PR) remains unclear to date (Yao S et al. 
2011). The majority of the studies were focused on the 
analysis of the relationship between pre-treatment levels 
of 25(OH)D and cancer development. There is no data 
regarding the influence of treatment on vitamin D status. 
The aim of the present study was to compare pre-
treatment and post-treatment levels of 25(OH)D in 
premenopausal and postmenopausal women with 
breast cancer and in healthy controls. The authors also 
aimed to analyse differential effects of 25(OH)D level 
by receptor status of the tumour type, estrogen receptor 
(ER) status, and progesterone receptor (PR) status. 
MATERIAL AND METHODS
The study included 49 patients with breast cancer (23 
premenopausal), and 28 healthy controls matched 
for age, menopausal status and BMI (25.2 kg/m2 vs. 
25.9 kg/m2, p=0.08). 
All the patients had undergone surgery, and sub-
sequently received standard adjuvant chemotherapy 
and, in selected cases, also radiotherapy. Additionally, 
patients with positive ER received hormone therapy 
after completing chemotherapy, and patients with posi-
tive human epidermal growth factor receptor 2 (HER2) 
expression received adjuvant immunotherapy (trastu-
zumab). Details are presented in Table 1.
Total 25(OH)D was assessed in blood samples using 
the immunochemistry method (ECLIA) with a Cobas 
e411 analyser (Roche Diagnostics GmbH, Mannheim, 
Germany).
Statistics
Statistical significance of differences between two inde-
pendent groups was assessed using the Mann-Whitney 
test or Student’s t- test.
Ethics
The investigation was conducted according to the prin-
ciples expressed in the Declaration of Helsinki. The 
study has been approved by the Jagiellonian University 
Bioethical Committee.
RESULTS
The level of pre-treatment 25(OH)D in patients with 
breast cancer was significantly lower in comparison to 
the control group (19 ng/mL vs. 30 ng/mL, p<0.001). 
The lowest level was observed in premenopausal 
women (18.4 ng/mL vs. 19.4 ng/mL in the postmeno-
pausal group), however, the difference was not signifi-
cant. After the treatment, the period control assessment 
revealed a significant decrease in 25(OH)D level (mean 
15.8 ng/mL) in the whole group, both in premeno-
pausal and postmenopausal women (16.6 and 15 ng/mL 
respectively). 
The pre-treatment level of 25(OH)D was signifi-
cantly lower in patients with the presence of ER in the 
tumour (16.1 vs. 23.9 ng/mL, p=0.02). The difference 
Tab. 1. Treatment methods in the investigated group.
Treatment No.
chemotherapy FEC 15
AC 9
AC /PTX
AT
14
RTX radiotherapy 37
hormone therapy tamoxifen 18
aromatase inhibitor 10
GnRH analogue 3
immunotherapy trastuzumab 16
FEC –5 fluorouracyl , epirubicin, cyclofosfamid
AC – doxorubicin , cyclofosfamid 
AC/PTX – doxorubicin , cyclofosfamid /PTX- paclitaxel weekly
AT – doxorubicin , taxotere
RTX – radiotherapy
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was observed also after completing the treatment. 
However, it was no longer significant (15 ng/mL vs. 
17.1 ng/mL, p=0.2).
Even greater differences were observed regarding 
the expression of PR. The level of 25(OH)D was sig-
nificantly lower in patients with the presence of PR in 
the tumour before the treatment (15 vs. 24.4 ng/mL, 
p=0.003), and after completing the treatment (13 ng/mL 
vs. 19.5 ng/mL, p=0.02).
The mean pre-treatment and post-treatment levels 
of 25(OH)D were lower in patients with Ki67 <21% 
(16.7 vs. 20.1 ng/mL, p=0.15; 12.5 vs. 18.1 ng/mL, 
p=0.02 respectively).
DISCUSSION
There has been long-standing interest in the potential 
role of vitamin D in the development of breast cancer, 
its recurrence and mortality, considering that, as a 
steroid-like molecule, it can modulate gene expression 
through binding to its specific nuclear receptor. The 
most important source of vitamin D is the conversion 
of dehydrocholesterol to cholecalciferol in the skin. In 
order to become a biologically active form of vitamin 
D, cholecalciferol undergoes two hydroxylation reac-
tions to 25(OH)D in the liver and subsequently to 
1.25(OH)2D in the kidneys. 1.25(OH)2D, also known 
as calcitriol, is a biologically active form of vitamin D. 
(Narvaez et al. 2014). Despite that calcitriol is an active 
form of vitamin D, its concentration level is not inves-
tigated routinely due to its very short half-life. It is 
better to measure the serum concentration of 25(OH)
D, which has a relatively longer half-life (approximately 
15 days). A large number of studies have related blood 
levels of 25(OH)D to cancer incidence and survival 
(Feldman et al. 2014; Albanes et al. 2015). 
It has been suggested that vitamin D and its metabo-
lites can reduce the incidence of many types of cancer 
by inhibiting tumour angiogenesis, stimulating mutual 
adherence of cells, and enhancing intercellular com-
munication through gap junctions, thereby strengthen-
ing the inhibition of proliferation which results from 
tight physical contact with adjacent cells within a tissue 
(contact inhibition). Vitamin D can inhibit the mito-
sis of breast epithelial cells. Pulsatile release of ionized 
calcium from intracellular stores, including the endo-
plasmic reticulum, induces terminal differentiation and 
apoptosis (Duffy et al. 2017).
Low blood levels of 25(OH)D have been associated 
with an increased risk of developing breast cancer and 
poor outcome following the diagnosis of this disease 
(Maalmi et al. 2014; Kim and Je, 2014; Mohr et al. 2014; 
Park et al. 2015). Other recently performed meta-anal-
yses, as well as large observational studies, have con-
firmed this inverse association between low levels of 
25(OH)D and both increased risk and poor outcome 
from breast cancer (Kim and Je, 2014; Mohret et al. 
2014; Park et al. 2015). The majority of the published 
data points to a close relationship between low 25(OH)
D3 and breast cancer risk in postmenopausal women, 
while disproving the existence of such a relationship 
in younger population (Garland et al. 2008; Kim et 
al. 2014). Our data indicates that a decreased level of 
25(OH)D has been observed in patients with breast 
cancer regardless of their menopausal status. 
However, while many studies have focused on the 
contribution of vitamin D deficiency to the breast 
cancer development, only a few included an analysis 
regarding different subtypes based on clinical markers 
such as ER and PR. Since breast cancer is a heterog-
enous group of the disease, clinical markers including 
ER and PR have long been used to classify breast cancer 
subtypes associated with differential prognosis and 
response to cancer therapy. Recently published studies 
showed that among premenopausal women with inva-
sive breast cancer, those who had lower serum 25OHD 
concentrations were at risk of development of high 
grade or ER negative cancer (Yao S et al. 2011, Abbas 
et al.,2008). There is no conclusive data pertaining to 
postmenopausal women. The results of the present 
study show that low levels of 25(OH)D can predispose 
to the development of ER and PR positive breast cancer 
in the premenopausal and postmenopausal women. 
Interestingly, the present study provided a novel 
insight in the form of a significant decrease in 25(OH)
D level during the course of therapy. As the positive role 
of vitamin D in the risk reduction of recurrence and a 
better overall prognosis have been described, it might 
be important to control the 25(OH)D level during the 
therapy and supplement vitamin D.
CONCLUSIONS
25(OH)D level is lower in patients with breast cancer 
in comparison to healthy women, irrespective of their 
menopausal status. The lowest levels are found in 
patients with ER and PR positive tumours. While a sig-
nificant decrease in 25(OH)D level during the course of 
the therapy is observed, the supplementation of vitamin 
D should be considered.
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